At present, pharmaceutical companies such as Apellis Pharmaceuticals (Pegcetacoplan), Iveric bio (Zimura), Genentech (Roche; RO7171009; RG6147), Ionis Pharmaceuticals/ Roche (IONIS-FB-LRx), Allegro Ophthalmics (Luminate), NGM Biopharmaceuticals (NGM621), Stealth BioTherapeutics (Elamipretide), Regenerative Patch Technologies (CPCB-RPE1), CellCure Neurosciences/Lineage Cell Therapeutics/ Roche (OpRegen), Gyroscope Therapeutics (GT005), and others, are working on developing a novel approach to treat Age-related Macular Degeneration (AMD).
The emerging therapies are based on different types of mechanisms of action, including C3 inhibitors, C5 inhibitors, Integrin Inhibitors, Anti-C1q antibody, Anti-C3 antibody, Factor D inhibitors, HtrA1, ASO Complement Factor B, and others.
“Age-related Macular Degeneration (AMD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Age-related Macular Degeneration Market.
The Age-related Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Age-related Macular Degeneration (AMD) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Age-related Macular Degeneration and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Age-related Macular Degeneration market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Learn How the Ongoing Clinical & Commercial Activities will Affect the Age-related Macular Degeneration Therapeutic Segment @
https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight
The Leading Companies in the Age-related Macular Degeneration (AMD) Therapeutics Market Include:
Alexion Pharmaceuticals, Alkahest Inc, Alkeus Pharmaceuticals, Allegro Ophthalmics, Annexon Biosciences, Apellis Pharmaceuticals, AstraZeneca, CellCure Neurosciences, Clearside Biomedical, Evergreen Therapeutics, Gemini Therapeutics, Graybug Vision, Gyroscope Therapeutics and Novartis, Ionis Pharmaceuticals, Iveric Bio, Kodiak Sciences Inc., Luxa Biotechnology, NGM Biopharmaceuticals, Novartis, Opthea Limited, Outlook Therapeutics, Inc., PanOptica, Inc., Regenerative Patch Technologies, Regeneron Pharmaceuticals, REGENXBIO, Ribomic USA Inc, Roche, Stealth BioTherapeutics, Unity Biotechnology, Inc, and many more.
Age-related Macular Degeneration Marketed and Emerging Drugs Covered in the Report Include:
Beovu (brolucizumab): Novartis
Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca
EG-301: Evergreen Therapeutics
Eylea (aflibercept): Regeneron Pharmaceuticals
KSI-301: Kodiak Sciences Inc.
Lucentis (ranibizumab): Roche
OPT-302: Opthea Limited
RGX-314: Regenxbio
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Age-related Macular Degeneration Current Treatment Patterns
4. Age-related Macular Degeneration – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Age-related Macular Degeneration Late Stage Products (Phase-III)
7. Age-related Macular Degeneration Mid-Stage Products (Phase-II)
8. Age-related Macular Degeneration Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Age-related Macular Degeneration Discontinued Products
13. Age-related Macular Degeneration Product Profiles
14. Key Companies in the Age-related Macular Degeneration Market
15. Key Products in the Age-related Macular Degeneration Therapeutics Segment
16. Dormant and Discontinued Products
17. Age-related Macular Degeneration Unmet Needs
18. Age-related Macular Degeneration Future Perspectives
19. Age-related Macular Degeneration Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Strategies
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
